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African horse sickness (AHS) is a hemorrhagic viral fever 
of horses. It is the only equine disease for which the World 
Organization for Animal Health has introduced specific 
guidelines for member countries seeking official recogni-
tion of disease-free status. Since 1997, South Africa has 
maintained an AHS controlled area; however, sporadic out-
breaks of AHS have occurred in this area. We compared 
the whole genome sequences of 39 AHS viruses (AHSVs) 
from field AHS cases to determine the source of 3 such out-
breaks. Our analysis confirmed that individual outbreaks 
were caused by virulent revertants of AHSV type 1 live, at-
tenuated vaccine (LAV) and reassortants with genome seg-
ments derived from AHSV types 1, 3, and 4 from a LAV used 
in South Africa. These findings show that despite effective 
protection of vaccinated horses, polyvalent LAV may, para-
doxically, place susceptible horses at risk for AHS.
African horse sickness (AHS) is a severe, often fa-tal disease of equids that is caused by AHS virus 
(AHSV), a member of the genus Orbivirus, family Reo-
viridae (1). The virus is transmitted to horses by biting 
midges in the genus Culicoides (2). Although AHS cur-
rently occurs only in sub-Saharan Africa, various species 
of Culicoides midges occur throughout the entire inhabit-
ed world, warranting concern that AHSV could spread into 
areas that are currently free of the virus (1,3–5). Further-
more, the global range of related Culicoides-transmitted 
orbiviruses, such as bluetongue virus, has expanded re-
cently, probably in part as a result of climate change (6). 
In AHS-endemic temperate regions, such as those occur-
ring throughout much of South Africa, the disease is most 
prevalent in late summer (7). Efforts to prevent the cata-
strophic impact of AHS began soon after the determina-
tion of its viral etiology in 1900, at which time it was only 
the second animal virus ever described (8,9). Presently, a 
polyvalent, live, attenuated vaccine (LAV) against AHSV 
(AHSV-LAV), which is produced by Onderstepoort Bio-
logical Products (Pretoria, South Africa) and provides 
broad protection against all 9 AHSV types (10), is used 
widely in South Africa and adjacent countries. This vac-
cine is supplied in 2 vials, each containing different com-
binations of AHSV types: combination 1 is trivalent and 
contains types 1, 3, and 4, whereas combination 2 is tetra-
valent and contains types 2, 6, 7, and 8 (10). Heterologous 
immunity is believed to provide protection to the 2 AHSV 
types, 5 and 9, that are not included in the vaccine.
AHS is the only equine disease for which the World 
Organisation for Animal Health (OIE) observes official 
recognition status, such that OIE member countries are re-
quired to have legally enforceable AHS control measures 
in place and are required to immediately notify OIE of any 
change to their country’s AHS status (11). The Western 
Cape Province of South Africa, at the southern tip of the 
African continent, has historically been free from AHS, 
and for this reason, a legislatively defined AHS controlled 
area was created there in 1997 to facilitate movement of 
horses from South Africa. Within this area are an AHS free 
zone, consisting of the Cape Town metropolis; an AHS sur-
veillance zone surrounding the free zone; and an outermost 
AHS protection zone (PZ) (Figure 1) (12). Movement of 
equids into and between these zones is strictly controlled. 
Vaccination with the polyvalent AHSV-LAV in the surveil-
lance zone and free zone is allowed only with permission 
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from the state veterinary service, and since March 2015, 
only during the period of low vector activity.
Since its creation in 1997, a total of 6 outbreaks of 
AHS in the AHS controlled area have been reported to 
OIE, in1999, 2004, 2006, 2011, 2013, and 2014 (13–17). 
Before the 2014 outbreak, these outbreaks were assumed 
to be caused by illegal movement of viremic animals into 
the controlled area, although the source was established for 
only 2 of these outbreaks: a type 7 virus for the 1999 out-
break in the surveillance zone and a type 5 virus for the 
2006 outbreak in the PZ (Figure 1) (18,19). Because the 
source of the viruses responsible for the other outbreaks 
was never established, the goal of our study was to further 
characterize the epidemiology of AHSV type 1 (AHSV-1) 
outbreaks in the controlled area by 1) whole-genome se-
quencing of viruses from individual outbreaks (2004, 2011, 
and 2014); 2) phylogenetic comparison of these sequences 
with those of the polyvalent AHSV-LAV and AHSV ref-
erence strains; 3) analysis of outbreak viruses for genome 
segment reassortment; 4) analysis of single-nucleotide vari-
ants (SNVs) associated with attenuation of AHSV-LAV to 
determine whether vaccine-derived viruses have reverted 
to virulence; 5) correlation of epidemiologic and clinical 
findings with molecular findings; and 6) confirmation of 
the source of the virus strains responsible for the 2004, 
2011, and 2014 outbreaks of AHS in the controlled area.
Materials and Methods
Virus Isolates
We sequenced complete genomes from 55 AHSV isolates 
collected during 1961–2014, including 39 field isolates of 
AHSV-1 from horses during the 2004 Stellenbosch (16 iso-
lates), 2011 Mamre (7 isolates), 2014 Porterville (14 iso-
lates), and 2014 Robertson (2 isolates) outbreaks of AHS in 
Western Cape Province of South Africa (Figure 1); AHSV 
LAV strains of types 1, 2, 3, 4, 6, 7, and 8; and Agricul-
tural Research Council–Onderstepoort Veterinary Institute 
Laboratory reference strains for each of the 9 AHSV types. 
We included each of these virus isolates in the AHS ge-
nome sequencing Bioproject (http://www.ncbi.nlm.nih.gov/
bioproject/?term=PRJNA271179) and identified each by a 
unique virus strain name (online Technical Appendix 1, http://
wwwnc.cdc.gov/EID/article/22/12/16-0718-Techapp1.xlsx). 
Figure 1. Locations of African 
horse sickness (AHS) outbreaks 
in Western Cape Province, South 
Africa, 2004–2014, including the 
spatial distribution of each of 
the AHS virus type 1 outbreaks 
that have occurred in the AHS 
controlled area since 1997. The 
AHS controlled area (shown in 
inset) is the combination of the 
AHS free, AHS surveillance, 
and AHS protection zones (also 
shown). Individual confirmed 
cases of AHS are indicated by 
solid dots. Half-shaded dots 
indicate confirmed cases for 
which samples were sent for 
sequencing (as opposed to 
confirmed cases that were not 
sequenced). The directional 
distribution of each outbreak is 
indicated by ellipses based on SD.
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RNA Extraction, Identification, and Typing
We isolated individual viruses of each type included in 
the polyvalent AHSV-LAV independently, as previously 
described (20,21). We extracted genomic double-stranded 
RNA from all AHSV strains evaluated from virus-infected 
cells by using TRIzol reagent (Life Technologies, Johan-
nesburg, South Africa). We identified and typed AHSV 
isolates by using group-specific (GS) real-time reverse 
transcription PCR (rRT-PCR) assays (22) and type-specific 
(TS) rRT-PCR assays targeting the gene encoding viral 
protein (VP) 2 (VP2) (23).
Genome Sequencing and Assembly
We prepared sequencing templates by using sequence-in-
dependent whole-genome RT-PCR amplification (24). We 
sequenced PCR amplicons on an Illumina MiSeq sequenc-
er (Inqaba Biotechnical Industries, Pretoria, South Africa) 
by using the Nextera XT DNA sample preparation kit and 
300-bp paired-end V3 Illumina chemistry. We analyzed Il-
lumina sequence reads by using Geneious version 9 (http://
www.geneious.com) (25). We used a combination of de 
novo assembly followed by mapping to obtain the full-
length consensus genome sequences of each virus strain.
Phylogenetic Analysis
We aligned sequences of the concatenated whole virus ge-
nomes and individual genome segments by using MAFFT 
(http://mafft.cbrc.jp/alignment/software) (26) implemented 
within Geneious version 9 (25). We then used the Smart 
Model Selection program included in PhyML version 3 
(http://www.atgc-montpellier.fr/phyml) (27) to identify the 
evolutionary models that best fit the individual sequence 
datasets by applying the corrected Akaike information cri-
terion. We used the parameters from these models to con-
struct maximum-likelihood trees by using PhyML version 
3 (27) implemented within Geneious version 9 (25) with 
1,000 bootstrap replicates to estimate branch support.
Genotype Group Analysis
We used RAMI (http://mbio-serv2.mbioekol.lu.se/rami.
html) to analyze the concatenated whole genome sequence 
maximum-likelihood tree to genetically (and not evolution-
arily) classify the sequences into genotype groups based on 
patristic distances (28). We ran RAMI with the patristic 
distance threshold set to 0.000459, enabling us to differ-
entiate between genome sequences that differed from one 
another by as few as 16 nt variants.
Reassortment Analysis
We used Recombination Detection Program (RDP) version 
4.63 (29) with default settings, except that we invoked the 
“scan for reassortment and recombination” setting to iden-
tify any reassortment between the gene segments of LAV 
strains of AHSV types 1, 3, and 4 and the 39 field isolate 
strains included in this study. We considered reassortment 
events detected by any of the 8 different recombination 
detection methods implemented in RDP (RDP, MAXCHI, 
and GENECONV methods in primary scanning mode and 
the BURT, Bootscan, CHIMAERA, SisScan, and 3SEQ 
methods in secondary scanning mode, each with a Bonfer-
roni corrected p value cutoff of 0.05) to represent evidence 
of reassortment.
Nonsynonymous Single Nucleotide Variants
We aligned consensus concatenated whole virus genomes 
from 2 AHSV-1 laboratory strains (1/Lab/ZAF/62/OVI-
HS29/62 and 1/Lab/ZAF/98/OBP-116) and the 39 field 
isolate strains by using MAFFT (26) and analyzed them by 
using the find variations/SNPs function in Geneious (25) 
with the find nonsynonymous polymorphisms only option 
enabled. We then compared the nonsynonymous SNVs in 
these sequences with the nonsynonymous SNVs previously 
associated with attenuation of AHSV-1 (24).
Results
Phylogenetic and Genotype Group Analysis
We used concatenated genome segments of 55 AHSV ge-
nomes to construct a maximum-likelihood phylogenetic 
tree incorporating best-fit substitution models (online 
Technical Appendix 2 Table 1, http://wwwnc.cdc.gov/
EID/article/22/12/16-0718-Techapp2.pdf) to infer degrees 
of genetic relatedness (Figure 2). Genotype group analysis 
of patristic distances inferred from this maximum-likeli-
hood tree by using RAMI (28) indicated that the AHSV 
strains isolated during the 2004, 2011, and 2014 outbreaks 
of AHS in the controlled area segregate into 3, 1, and 2 
unique groups, respectively. Specifically, the groups were 
1a, 1b, and 1c for the 2004 outbreak; 2 for the 2011 out-
break; 3a for the 2014 Porterville outbreak; and 3b for the 
2014 Robertson outbreak (online Technical Appendix 2 
Table 2). For the 2004 outbreak viruses, genotype group 
1a includes 4 viruses that group closely with the AHSV-1-
LAV strain, 1/Lab/ZAF/98/OBP-116; genotype group 1b 
includes 11 viruses that are also closely related to 1/Lab/
ZAF/98/OBP-116; and genotype group 1c includes a single 
virus that segregates between 1/Lab/ZAF/98/OBP-116 and 
4/Lab/ZAF/98/OBP-116. The Mamre outbreak viruses in 
genotype group 2 consist of 7 viruses that are all closely 
related to 1/Lab/ZAF/98/OBP-116. For the 2014 outbreak 
viruses, genotype group 3a includes 14 viruses that were 
all isolated from AHSV-infected horses in the Porterville 
area and genotype group 3b includes 2 viruses that were 
isolated from AHSV-infected horses in the Robertson area, 
with both groups of viruses being closely related to 1/Lab/
ZAF/98/OBP-116. 
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Given that reassortment is a major feature of orbivirus 
evolution (30,31), we further explored the evolutionary re-
lationships between the 55 AHSV sequences by construct-
ing separate maximum-likelihood trees for each of the 
VP1, VP2, VP3, VP4, VP5, VP6, VP7, nonstructural (NS) 
protein 1 (NS1), NS2, and NS3 encoding genome segments 
(online Technical Appendix 2 Figures 1–10). For the seg-
ments encoding VP2, VP3, VP6, NS1, and NS2, viruses 
included in genotype groups 1a, 1b, 1c, 2, 3a, and 3b all 
group, with high degrees of associated bootstrap support, 
together with the AHSV-1-LAV strain, 1/Lab/ZAF/98/
OBP-116. For the segments encoding VP1, VP4, and VP7, 
the viruses included in genotype groups 1a, 2, 3a, and 3b 
also group with 1/Lab/ZAF/98/OBP-116, whereas those 
in genotype groups 1b and 1c group with the AHSV-3-
LAV strain, 3/Lab/ZAF/98/OBP-116. For the gene encod-
ing VP5, viruses included in all genotype groups except 
1c group with 1/Lab/ZAF/98/OBP-116, whereas those in 
genotype group 1c group with the AHSV-4-LAV strain, 4/
Lab/ZAF/98/OBP-116. For genes encoding NS3, viruses 
included in genotype groups 1a and 2 group with 1/Lab/
ZAF/98/OBP-116, whereas those included in the remaining 
genotype groups group with 4/Lab/ZAF/98/OBP-116. Col-
lectively, these data confirm that all 10 gene segments of 
 
 
 
Table 1. Attenuation-associated nonsynonymous SNVs of consensus sequences of genome segments of AHSV-1 viruses from 4 AHS 
outbreaks in the AHS controlled area of Western Cape Province, South Africa, 2004–2014, and reference strains* 
Abbreviated strain name 
Genome segment and amino acid position Genotype 
group VP2 357 VP3 232 VP5 422 VP5 434 VP6 81 VP6 169 NS3 201 
1/E.cab-tc/ZAF/62/OVI-HS29/62 N Y S T A R M 
 
1/Lab/ZAF/98/OBP-116† K H N I V Q K 
 
1/E.cab-tc/ZAF/04/Elb-E040019 ‡ 
  
T§ A R E 1a 
1/E.cab-tc/ZAF/04/Elb-E040020  
  
T A R E 1a 
1/E.cab-tc/ZAF/04/Elb-E040021  
  
T A R E 1a 
1/E.cab-tc/ZAF/04/Dkt-E040029  
  
T A R E 1a 
1/E.cab-tc/ZAF/04/Tgd-E040031 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Elb-E040034 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Tgd-E040039 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Avt-E040043 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Avt-E040048 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Vdm-E040062 N   T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Tgd-E040064 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Vdm-E040065 N 
  
T A 
 
¶ 1b 
1/E.cab-tc/ZAF/04/Avt-E040066 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Avt-E040081 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Kbk-E040086 N 
  
T A R ¶ 1b 
1/E.cab-tc/ZAF/04/Avt-E040061 N 
 
¶ ¶ A R ¶ 1c 
1/E.cab-tc/ZAF/11/Mre-E110143_1    T A R N 2 
1/E.cab-tc/ZAF/11/Mre-E110180_WC44  
  
T A R N 2 
1/E.cab-tc/ZAF/11/Mre-E110180_WC61  
  
T A R N 2 
1/E.cab-tc/ZAF/11/Mre-E110180_WC165  
  
T A R N 2 
1/E.cab-tc/ZAF/11/Mre-E110411_1  
  
T A R N 2 
1/E.cab-tc/ZAF/11/Mre-E110418_1  
  
T A R N 2 
1/E.cab-tc/ZAF/11/Mre-E110674_3  
  
T A R N 2 
1/E.cab-tc/ZAF/14/Ptv-E140485_WC00522  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140485_WC00528  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140485_WC00533  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140485_WC00544  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140485_WC00555  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Srn-E140526_WC00481 
   
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Srn-E140526_WC00482  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Srn-E140526_WC00488  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Srn-E140526_WC00491  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Srn-E140526_WC00493  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Srn-E140526_WC00502  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140536_WC00506  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140536_WC00507  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Ptv-E140536_WC00508  
  
T A R ¶ 3a 
1/E.cab-tc/ZAF/14/Rbn-E140702_RB00008  
  
T A R ¶ 3b 
1/E.cab-tc/ZAF/14/Rbn-E140816_RB00221  
  
T A R ¶ 3b 
*AHS, African horse sickness; AHSV-1, AHS virus type 1; NS3, nonstructural protein 3; SNV, single-nucleotide variants; VP, viral protein. 
†The changes in amino acids are indicated in comparison with the AHSV-1 live, attenuated vaccine-derived strain (1/Lab/ZAF/98/OBP-116) for relevant 
viral proteins. 
‡Sequences that were identical to the consensus sequence of the vaccine-derived strain are indicated by an empty cell. 
§Sequences that differed from the consensus sequence of the AHSV-1 live, attenuated vaccine-derived strain are indicated with the letter symbol of the 
relevant amino acid. 
¶Indicates that these segments were not considered due to a recombination event that occurred with another vaccine-derived AHSV type. 
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the viruses included in genotype groups 1a and 2 are prob-
ably derived from a most recent common ancestor closely 
resembling 1/Lab/ZAF/98/OBP-116; the viruses included 
in genotype groups 1b and 1c are probably reassortants de-
rived from parental viruses very closely resembling 1/Lab/
ZAF/98/OBP-116, 3/Lab/ZAF/98/OBP-116, and 4/Lab/
ZAF/98/OBP-116; and viruses in genotype groups 3a and 
3b are probably reassortants derived from parental viruses 
very closely resembling 1/Lab/ZAF/98/OBP-116 and 4/
Lab/ZAF/98/OBP-116 (Figure 3).
Figure 2. Whole-genome 
phylogeny of African horse 
sickness (AHS) viruses identified 
in AHS outbreaks in Western 
Cape Province, South Africa, 
2004–2014. Maximum-likelihood 
phylogenetic tree indicating 
the genetic relationships of 
concatenated whole genome 
nucleotide sequences of AHS 
viruses from affected horses in the 
2004, 2011, and 2014 outbreaks in 
the AHS controlled area in Western 
Cape Province to the AHS live, 
attenuated vaccine viruses and 
reference viruses. Green indicates 
vaccine-derived 1/Lab/ZAF/98/
OBP-116, blue indicates vaccine-
derived 3/Lab/ZAF/98/OBP-116, 
and red indicates vaccine-derived 
4/Lab/ZAF/98/OBP-116. Branches 
are scaled to represent numbers 
of inferred nucleotide differences 
per site. Branches supported by 
full maximum-likelihood bootstrap 
values >70% are indicated. 
Genotype groups are indicated  
at right. Scale bar indicates  
genetic distance.
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Explicitly testing for intrasegment recombination and 
reassortment by using RDP4.63 (29) yielded no evidence 
of intracomponent recombination in any virus but strong 
evidence of reassortment in genotype group 1b, 1c, 3a, and 
3b viruses (online Technical Appendix 2 Table 3). Geno-
type group 1b viruses have 6 genome segments (encoding 
VP2, VP3, VP5, VP6, NS1, and NS2) derived from a vi-
rus resembling 1/Lab/ZAF/98/OBP-116; 2 segments (en-
coding VP1 and VP7) derived from a virus resembling 3/
Lab/ZAF/98/OBP-116 (multiple testing corrected p = 2.27 
× 10–12 and 1.13 × 10–31, respectively); 1 segment (encod-
ing NS3) derived from a virus resembling 4/Lab/ZAF/98/
OBP-116 (p = 9.31 × 10–240); and 1 segment (encoding 
VP4) that could plausibly have been derived from ei-
ther 3/Lab/ZAF/98/OBP-116 or 1/Lab/ZAF/98/OBP-116 
(p = 7.66 × 10–4) (Figure 4). Genotype group 1c viruses 
display a reassortant pattern resembling that of group 1b 
viruses except that the segment encoding VP5 is apparently 
derived from a virus resembling 4/Lab/ZAF/98/OBP-116 
(p = 1.96 × 10–216). Genotype groups 3a and 3b viruses have 
9 segments derived from a virus resembling 1/Lab/ZAF/98/
OBP-116 and a single segment (NS3) derived from a 
virus resembling 4/Lab/ZAF/98/OBP-116 (p = 9.31 × 10–240) 
(Figure 4).
Several SNVs relative to the AHSV-LAV–derived 
viruses 1/Lab/ZAF/98/OBP-116 and 3/Lab/ZAF/98/OBP-
116 are present in the NS1-encoding genes of viruses in-
cluded in genotype groups 3a (2014 Porterville) and 3b 
(2014 Robertson) (online Technical Appendix 2 Table 4). 
Only a single nonsynonymous SNV exists between the 
NS1-encoding genes of 1/Lab/ZAF/98/OBP-116 and 3/
Lab/ZAF/98/OBP-116 (NS1 I264T). All viruses included 
in genotype group 3a (2014 Porterville) have the I amino 
acid variant that is present in 1/Lab/ZAF/98/OBP-116, 
whereas viruses in genotype group 3b (2014 Robertson) 
include the T amino acid variant present in 3/Lab/ZAF/98/
OBP-116. Viruses in the 3b genotype group (2014 Robert-
son) include >2 synonymous SNVs and >1 nonsynonymous 
SNV relative to 3/Lab/ZAF/98/OBP-116, which suggests 
that the NS1 gene of the virus strains in genotype group 3b 
are most probably derived from 3/Lab/ZAF/98/OBP-116, 
whereas those in genotype group 3a are more probably de-
rived from 1/Lab/ZAF/98/OBP-116.
Seven nonsynonymous SNVs were identified between 
the whole genome sequences of the AHSV-1-LAV–de-
rived virus, 1/Lab/ZAF/98/OBP-116, and its parental vi-
rus, 1/E.cab-tc/ZAF/62/OVI-HS29/62 (Table 1). SNVs 
are present at 4 of these 7 sites in the 4 viruses included in 
genotype group 1a. Intriguingly, 3 of these 4 changes are 
apparently reversions to the nonsynonymous SNV that is 
present in the virulent parental virus (I434T in VP5 and 
V81A and Q169R in VP6) and are therefore potentially 
reversion-to-virulence mutations. The 1 other SNV in the 
genotype group 1a viruses is site 201 in NS3, whereas 
in 1/Lab/ZAF/98/OBP-116 and 1/E.cab-tc/ZAF/62/OVI-
HS29/62, a K and an M, respectively, are at this site, and 
in the group 1a viruses, an E is at this site. In 10 of the 
11 field viruses in genotype group 1b, nonsynonymous 
SNVs were also detected at 4 of the 7 sites that differ-
entiate the attenuated 1/Lab/ZAF/98/OBP-116 virus from 
its virulent parent, 1/E.cab-tc/ZAF/62/OVI-HS29/62. The 
remaining field virus in genotype group 1b, 1/E.cab-tc/
ZAF/04/Vdm-E040065, includes 3 of these 4 SNVs. The 
I434T SNV in VP5 and the V81A and Q169R SNVs in 
VP6 of viruses in genotype group 1a are the same as those 
found in the genotype group 1b, 2, 3a, and 3b viruses. The 
K357N SNV in VP2 was detected only among viruses in 
genotype groups 1b and 1c. All the viruses included in 
genotype groups 1b, 1c, 3a, and 3b are also reassortants 
with an NS3-encoding segment derived from a virus re-
sembling 4/Lab/ZAF/98/OBP-116; therefore, SNVs in 
this component of these viruses were not considered as 
genuine mutationally derived SNVs.
The 1/E.cab-tc/ZAF/04/Avt-E040061 strain in gen-
otype group 1c has nonsynonymous SNVs at 3 of the 7 
loci (K357N in VP2 and V81A and Q169R in VP6) but a 
 
 
 
Table 2. Epidemiologic parameters for 4 outbreaks involving AHS virus type 1 in the AHS controlled area in Western Cape Province, 
South Africa, 2004–2014* 
Parameter† 2004 Stellenbosch 2011 Mamre 2014 Porterville 2014 Robertson 
No. confirmed cases 23 (16)‡ 84 (73)§ 89 22 
No. deaths 18 (16)‡ 64 (64)§ 13 1 
Case-fatality rate, % 78.3 (100)‡ 76.2 (87.7)§ 14.6 4.5 
No. subclinical cases 0 15 (4)† 52 17 
 % Subclinical 0 17.9 (5.5)§ 58.4 77.3 
No. vaccinated cases 2/23 2/84 35/89 3/22 
 % Vaccinated 8.7 2.4 39.3 13.6 
No. properties affected 10 (8)‡ 47 (45)§ 31 8 
*AHS, African horse sickness. 
†The parameters were calculated by using the current World Organization for Animal Health (OIE) case definition. Parameters calculated by using the 
case definitions when the outbreaks occurred are in parenthesis for the 2004 and 2011 outbreaks. 
‡An additional 5 clinical cases and 2 deaths that met the criteria of the current OIE AHS case definition were not included based on the case definition in 
place at the time of this outbreak (13). 
§An additional 11 subclinical cases that met the criteria of the current OIE AHS case definition were not included based on the case definition in place at 
the time of this outbreak (15). 
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VP5-encoding gene apparently derived by reassortment 
from a virus resembling 4/Lab/ZAF/98/OBP-116, such that 
the SNVs in the VP5 of this strain were also not considered 
to be mutationally derived.
The 7 viruses included in genotype group 2 and the 
16 viruses included in genotype groups 3a and 3b all ex-
hibit potential reversion-to-virulence mutations at 3 of the 
7 nonsynonymous SNV sites that differentiate the AHSV-
1-LAV virus from its virulent parent (I434T in VP5 and 
V81A and Q169R in VP6). Additionally, a fourth SNV 
(K201N in NS3) at 1 of the 7 sites differentiating the 
AHSV-1 LAV from its parent (which had a K and an M, 
respectively, at this site) is also present in the genotype 
group 2 viruses.
Quantification of the Outbreaks
The epidemiologic parameters of the AHS outbreaks in 
the controlled area in 2004, 2011, and 2014 were inferred 
by using the current OIE case definition for AHS (11) 
(Table 2). Although the case-fatality rates (CFRs) were 
very high for the 2004 Stellenbosch (78.3%) and 2011 
Mamre (76.2%) outbreaks, they were considerably lower 
for the 2014 Porterville (14.6%) and Robertson (4.5%) 
outbreaks. Additionally, the 2011 Mamre and 2004 Stel-
lenbosch outbreaks were associated with the lowest vac-
cination rates among AHSV-infected horses (2.7% and 
8.7%, respectively). Differences in the genetic constitu-
tion of the individual outbreak viruses could have been as-
sociated with the vastly different CFRs in each outbreak; 
however, whether these differences in CFRs are a conse-
quence of lower virulence among the outbreak viruses or 
the result of existing vaccine-induced immunity in the ex-
posed horses is unknown. Similarly, changes in the AHS 
case definition that only came into effect in 2008 (after the 
2004 Stellenbosch outbreak) probably resulted in an un-
derestimation of subclinical AHSV infections during that 
outbreak. Whereas during the Stellenbosch 2004 outbreak 
only clinically affected, deceased horses were classified 
Figure 3. Cladogram and 
heat map of vaccine-derived 
African horse sickness (AHS) 
virus reassortants identified 
in AHS outbreaks in Western 
Cape Province, South Africa, 
2004–2014. Cladogram 
indicates genetic relationships of 
concatenated AHS virus whole-
genome nucleotide sequences 
from affected horses in the 
2004, 2011, and 2014 outbreaks 
in the AHS controlled area in 
Western Cape Province. Heat 
map diagram summarizes the 
origin of the gene segments for 
each strain with 1/Lab/ZAF/98/
OBP-116 (green blocks), 3/Lab/
ZAF/98/OBP-116 (blue blocks), 
and 4/Lab/ZAF/98/OBP-116 
(red blocks) vaccine-derived 
strains. Gray blocks indicate that 
the segment could be derived 
from either 1/Lab/ZAF/98/OBP-
116 or 3/Lab/ZAF/98/OBP-116. 
Branches supported by full 
maximum-likelihood bootstrap 
values >70% are indicated. 
Genotype groups are indicated 
at right.
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as having confirmed cases (13), major advances in AHS 
diagnostic testing (e.g., rRT-PCR–based methods) have 
occurred during the past 10 years that likely substantially 
increased the detection of subclinical infections by the 
time of the 2014 outbreaks (15,32).
Discussion
Whole-genome sequences were compared from 55 field, 
LAV, and laboratory strains of AHSV. The field viruses 
were obtained from horses during outbreaks of AHS of 
different clinical severity (CFRs ranging from 4.5% to 
78.3%) in the AHS controlled area of South Africa during 
2004, 2011, and 2014. Phylogenetic analyses confirmed 
that genetically distinct viruses were responsible for each 
outbreak and that these were all closely related to viruses 
contained in the trivalent AHSV-LAV (combination 1) 
used in South Africa. Evaluation of nonsynonymous SNVs 
confirmed some outbreak viruses to be revertants of the 
vaccine AHSV-1 strain toward the virulent parental type. 
Furthermore, some outbreak viruses were clearly reassor-
tants with individual genome segments derived from mul-
tiple different virus types that are present in the trivalent 
vaccine preparation.
Potgieter et al. (24) hypothesized that changes in VP2 
and VP5 can confer virulence or attenuation of individual 
AHSV strains, based upon comparisons of the consen-
sus sequences of the genome of an attenuated AHSV-1 
isolate (GenBank accession nos. FJ183364–FJ183373) 
and its virulent parent. Potgieter et al. (24) also proposed 
that virulence is related to tissue tropism because the out-
er capsid proteins are involved in cell entry and trigger 
apoptosis of host cells. Additionally, other studies have 
implicated NS3 as a determinant of AHSV virulence (33). 
The results of our study further confirm that changes in 
multiple VPs can affect the virulence of AHSV. Both re-
version (to the virulent parental type) and novel SNVs 
were present in field-isolated viruses at various residue 
sites in VP2 (K357N in genotype group 1b viruses), VP5 
(I434T in all field viruses evaluated except sample 1/E.
cab-tc/ZAF/04/Avt- E040061), and VP6 (V81A in all 
field viruses and Q169R in all field viruses except sample 
1/E.cab-tc/ZAF/04/Vdm-E040065) that differentiate the 
attenuated AHSV-1-LAV strain from its virulent paren-
tal strain. Furthermore, SNVs present at a site in NS3 
(K201E in genotype group 1a viruses and K201N in geno-
type group 2) are potentially associated with reversion to 
virulence because of the effect of NS3 on virus release, 
membrane permeability, and viral yield (34). However, 
the determinants of AHSV virulence are probably com-
plex and multigenic (24,34), which is consistent with the 
remarkable difference in CFRs between horses in the var-
ious outbreaks.
Given the genetic diversity of field strains of AHSV 
(14,24,35), our analyses overwhelmingly support the 
Figure 4. Statistical evidence 
of reassortment within the 
genomes of African horse 
sickness (AHS) virus field 
isolates identified in outbreaks 
in the AHS controlled area 
in Western Cape Province, 
South Africa, 2004–2014. A 
hidden Markov model–based 
approach (BURT-HMM) was 
used to classify individual 
nucleotides within each of 
the 10 segments of individual 
AHS virus isolates into 
3 different categories: 1/
Lab/ZAF/98/OBP-116-like 
(green), 3/Lab/ZAF/98/OBP-
116-like (blue), and 4/Lab/
ZAF/98/OBP-116-like (red). 
Probability supports for these 
classifications yielded by the 
BURT-HMM with the highest 
likelihood are plotted along the 
genome. Positions of segment 
boundaries are given in the 
diagram above the plots. The 
phylogenetic clusterings that 
are implied by differently colored segments in these plots are indicated below the plots. The segment indicated in gray could not be 
convincingly classified because it closely resembles both 1/Lab/ZAF/98/OBP-116 and 3/Lab/ZAF/98/OBP-116.
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premise that the potential reversion-to-virulence mutants 
and reassortants that we detected arose from viruses within 
the polyvalent AHSV-LAV formulation, and predomi-
nantly from AHSV-1-LAV. Although these mutants and 
reassortants most likely arose within vaccinated horses, the 
reason for the predominance of AHSV-1-LAV components 
in the emergent outbreak viruses is unknown. The data pre-
sented here also indicate that distinct founder events led to 
the expansion in Stellenbosch (2004) of viruses included 
in genotype groups 1a and 1b and, similarly, that the out-
breaks in 2014 in Porterville (genotype group 3a) and Rob-
ertson (genotype group 3b) also probably originated inde-
pendently from the LAV and were not from the spread of 
the same outbreak virus.
In summary, results of this study highlight the im-
portance of genetic characterization of circulating strains 
of AHSV in epidemiologic investigations of AHS out-
breaks. Although, the prevailing opinion in South Africa 
was that illegal movement of viremic equids into the AHS 
controlled area was responsible for the repeated occur-
rences of AHS in the controlled area, this is clearly not 
the only cause. Our data confirm that use of polyvalent 
AHSV-LAV can result in the emergence and spread of 
virulent viruses to adjacent susceptible horses, presum-
ably by Culicoides midge vectors that are already resi-
dent within the AHS controlled area (36). Collectively, 
these findings have major implications for strategies to 
control AHS, both in AHS-endemic regions and during 
future incursions into currently AHSV-free areas. How-
ever, AHSV-LAV confers critical and effective protec-
tion for susceptible horses in AHS-endemic areas and, 
although potentially safer recombinant AHSV vaccines 
have proven effective in laboratory studies (37,38), 
these are not available commercially and they are yet to 
be evaluated in the field. Until alternative vaccines be-
come commercially available, control of AHS will re-
main reliant on the use of AHSV-LAV coupled with the 
adoption of strategies to minimize the likelihood of nat-
ural dissemination of revertant and reassortant vaccine- 
derived viruses.
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Strain Namea Abbreviated Strain Nameb BioSample Number Assession Numbers Coverage Animal Name/Source Reference Genotype Group Outcome Sample Sampled Vaccinationc
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Elsenburg-E040019 1/E.cab-tc/ZAF/04/Elb-E040019 SAMN04038467 KT715641 - KT715650 101369 Laura [23, 24, 25] 1a Died Organs 22/02/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Elsenburg-E040020 1/E.cab-tc/ZAF/04/Elb-E040020 SAMN03774773 KT186897 - KT186906 3823 Michelle [23, 24, 25] 1a Died Organs 22/02/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Elsenburg-E04002 1/E.cab-tc/ZAF/04/Elb-E040021 SAMN03774774 KT186907 - KT186916 11093 Mara [23, 24, 25] 1a Died Blood 24/02/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Daktari-E040029 1/E.cab-tc/ZAF/04/Dkt-E040029 SAMN03774771 KT186917 - KT186926 9984 Murphy Brown [23, 24, 25] 1a Died Blood 28/02/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Troughend-E040031 1/E.cab-tc/ZAF/04/Tgd-E040031 SAMN03774781 KT186927 - KT186936 5223 SA Saddlehorse 1 [23, 24, 25] 1b Died Organs 26/02/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Elsenburg-E040034 1/E.cab-tc/ZAF/04/Elb-E040034 SAMN03774775 KT186937 - KT186946 13476 Mandy [23, 25] 1b Recovered Blood 26/02/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Troughend-E040039 1/E.cab-tc/ZAF/04/Tgd-E040039 SAMN03774782 KT186947 - KT186956 9825 Melody Fire [23, 25] 1b Recovered Blood 03/03/2004 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Avontuur-E040043 1/E.cab-tc/ZAF/04/Avt-E040043 SAMN03774767 KT186957 - KT186966 4683 Bow Street Bell [23, 24, 25] 1b Euthanased Blood 04/03/2004 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Avontuur-E040048 1/E.cab-tc/ZAF/04/Avt-E040048 SAMN03774768 KT186967 - KT186976 10113 Bow Street Bell [23, 24, 25] 1b Euthanased Organs 09/03/2004 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Vredenheim-E040062 1/E.cab-tc/ZAF/04/Vdm-E040062 SAMN03774784 KT186987 - KT186996 10978 Bruin Perd [23, 24, 25] 1b Died Blood 15/03/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Troughend-E040064 1/E.cab-tc/ZAF/04/Tgd-E040064 SAMN03774783 KT186997 - KT187006 11652 SA Saddlehorse 2 [23, 24, 25] 1b Died Organs 17/03/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Vredenheim-E040065 1/E.cab-tc/ZAF/04/Vdm-E040065 SAMN03774785 KT187007 - KT187016 5823 Bruin Perd [23, 24, 25] 1b Died Organs 17/03/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Avontuur-E040066 1/E.cab-tc/ZAF/04/Avt-E040066 SAMN03774769 KT187017 - KT187026 4128 Special Edition [23, 24, 25] 1b Died Organs 18/03/2004 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Avontuur-E040081 1/E.cab-tc/ZAF/04/Avt-E040081 SAMN03774770 KT187037 - KT187046 15663 2003Stars and Stripes [23, 24, 25] 1b Died Organs 24/03/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Kalbaskraal-E040086 1/E.cab-tc/ZAF/04/Kbk-E040086 SAMN03774776 KT187047 - KT187056 7654 Amber [23, 24, 25] 1b Died Organs 29/03/2004 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2004/Avontuur-E040061 1/E.cab-tc/ZAF/04/Avt-E040061 SAMN03780052 KT186977 - KT186986 11336 Special Edition [23, 24, 25] 1c Died Blood 16/03/2004 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110143_1 1/E.cab-tc/ZAF/11/Mre-E110143_1 SAMN03765259 KT070447 - KT070456 3017 Ruben [26] 2 Died Organs 27/02/2011 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110180_WC165 1/E.cab-tc/ZAF/11/Mre-E110180_WC165 SAMN03765262 KT070477 - KT070486 3567 Trigger [26] 2 Died Organs 06/03/2011 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110180_WC61 1/E.cab-tc/ZAF/11/Mre-E110180_WC61 SAMN03765261 KT070507 - KT070516 5300 Jordan [26] 2 Subclinical Blood 06/03/2011 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110180_WC44 1/E.cab-tc/ZAF/11/Mre-E110180_WC44 SAMN03765260 KT070487 - KT070496 2970 Smokey [26] 2 Recovered Blood 06/03/2011 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110418_1 1/E.cab-tc/ZAF/11/Mre-E110418_1 SAMN03765264 KT070497 - KT070506 6806 Moon [26] 2 Died Organs 22/03/2011 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110411_1 1/E.cab-tc/ZAF/11/Mre-E110411_1 SAMN03765263 KT070457 - KT070466 4566 Dusty [26] 2 Died Organs 26/03/2011 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2011/Marme-E110674_3 1/E.cab-tc/ZAF/11/Mre-E110674_3 SAMN03765265 KT070467 - KT070476 6847 Robin [26] 2 Recovered Blood 18/04/2011 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Saron-E140526_WC00502 1/E.cab-tc/ZAF/14/Srn-E140526_WC00502 SAMN03769430 KT187187 - KT187196 10105 McGuiver TS 3a Subclinical Blood 24/03/2014 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Saron-E140526_WC00493 1/E.cab-tc/ZAF/14/Srn-E140526_WC00493 SAMN03769429 KT187177 - KT187186 13406 Milky TS 3a Subclinical Blood 24/03/2014 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Saron-E140526_WC00481 1/E.cab-tc/ZAF/14/Srn-E140526_WC00481 SAMN03769427 KT187137 - KT187146 7881 Ballaka TS 3a Subclinical Blood 24/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Saron-E140526_WC00488 1/E.cab-tc/ZAF/14/Srn-E140526_WC00488 SAMN03769428 KT187157 - KT187166 18131 King TS 3a Subclinical Blood 24/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Saron-E140526_WC00491 1/E.cab-tc/ZAF/14/Srn-E140526_WC00491 SAMN03774780 KT187167 - KT187176 8216 Fire TS 3a Recovered Blood 24/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Saron-E140526_WC00482 1/E.cab-tc/ZAF/14/Srn-E140526_WC00482 SAMN03774779 KT187147 - KT187156 8624 Raily TS 3a Died Blood 24/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140536_WC00507 1/E.cab-tc/ZAF/14/Ptv-E140536_WC00507 SAMN03769425 KT187207 - KT187216 12686 Jahan Zahmar TS 3a Recovered Blood 27/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140536_WC00508 1/E.cab-tc/ZAF/14/Ptv-E140536_WC00508 SAMN03769426 KT187217 - KT187226 10474 Jahan Dajinah TS 3a Recovered Blood 27/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140536_WC00506 1/E.cab-tc/ZAF/14/Ptv-E140536_WC00506 SAMN03769424 KT187197 - KT187206 14902 Jahan Nasibah TS 3a Recovered Blood 27/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140485_WC00522 1/E.cab-tc/ZAF/14/Ptv-E140485_WC00522 SAMN03769419 KT187077 - KT187086 15126 Jahan Faraj TS 3a Recovered Blood 31/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140485_WC00544 1/E.cab-tc/ZAF/14/Ptv-E140485_WC00544 SAMN03769422 KT187117 - KT187126 9638 Jahan Dhia TS 3a Subclinical Blood 31/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140485_WC00528 1/E.cab-tc/ZAF/14/Ptv-E140485_WC00528 SAMN03769420 KT187097 - KT187106 10108 Jahan Jihad TS 3a Recovered Blood 31/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140485_WC00533 1/E.cab-tc/ZAF/14/Ptv-E140485_WC00533 SAMN03769421 KT187107 - KT187116 8122 Jahan Al Rabiah TS 3a Recovered Blood 31/03/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Porterville-E140485_WC00555 1/E.cab-tc/ZAF/14/Ptv-E140485_WC00555 SAMN03769423 KT187127 - KT187136 5588 el-Jahrousse Mia TS 3a Recovered Blood 31/03/2014 Vaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Robertson-E140702_RB00008 1/E.cab-tc/ZAF/14/Rbn-E140702_RB00008 SAMN03774777 KT187087 - KT187096 6356 2013Hersonet TS 3b Recovered Blood 25/04/2014 Unvaccinated
African horse sickness virus 1 strain 1/E.caballus-tc/ZAF/2014/Robertson-E140816_RB00221 1/E.cab-tc/ZAF/14/Rbn-E140816_RB00221 SAMN03774778 KT187227 - KT187236 6721 2013Tale Of The Glacier TS 3b Subclinical Blood 08/05/2014 Unvaccinated
African horse sickness virus 1 strain 1/Labstr/ZAF/1998/OBP-116 1/Lab/ZAF/98/OBP-116 SAMN03764401 KT030330 - KT030339 7547 OBP AHSV1 LAV, Batch 116 [41]
African horse sickness virus 2 strain 2/Labstr/ZAF/1998/OBP-252.1 2/Lab/ZAF/98/OBP-252.1 SAMN04038462 KT715601 - KT715610 29050 OBP AHSV2 LAV, Batch 252.1 [42]
African horse sickness virus 3 strain 3/Labstr/ZAF/1998/OBP-116 3/Lab/ZAF/98/OBP-116 SAMN03764402 KT030340 - KT030349 11756 OBP AHSV3 LAV, Batch 116 [41]
African horse sickness virus 4 strain 4/Labstr/ZAF/1998/OBP-116 4/Lab/ZAF/98/OBP-116 SAMN03764403 KT030350 - KT030359 6977 OBP AHSV4 LAV, Batch 116 [41]
African horse sickness virus 6 strain 6/Labstr/ZAF/1998/OBP-252.1 6/Lab/ZAF/98/OBP-252.1 SAMN04038463 KT715611 - KT715620 35724 OBP AHSV6 LAV, Batch 252.1 [42]
African horse sickness virus 7 strain 7/Labstr/ZAF/1998/OBP-252.1 7/Lab/ZAF/98/OBP-252.1 SAMN04038464 KT715621 - KT715630 137497 OBP AHSV7 LAV, Batch 252.1 [42]
African horse sickness virus 8 strain 8/Labstr/ZAF/1998/OBP-252.1 8/Lab/ZAF/98/OBP-252.1 SAMN04038465 KT715631 - KT715640 120396 OBP AHSV8 LAV, Batch 252.1 [42]
African horse sickness virus 1 strain 1/Labstr/ZAF/1962/OVI-HS29/62 1/Lab/ZAF/62/OVI-HS29/62 SAMN03765190 KT030570 - KT030579 8401 ARC-OVI OIE Laboratory Reference Strain AHSV1 [44], TS
African horse sickness virus 2 strain 2/Labstr/ZAF/1961/OVI-HS82/61 2/Lab/ZAF/61/OVI-HS82/61 SAMN03765191 KT030580 - KT030589 7698 ARC-OVI OIE Laboratory Reference Strain AHSV2 [44], TS
African horse sickness virus 3 strain 3/Labstr/ZAF/1963/OVI-HS13/63 3/Lab/ZAF/63/OVI-HS13/63 SAMN03765192 KT030590 - KT030599 5281 ARC-OVI OIE Laboratory Reference Strain AHSV3 [44], TS
African horse sickness virus 4 strain 4/Labstr/ZWE/1962/OVI-HS32/62 4/Lab/ZWE/62/OVI-HS32/62 SAMN03765193 KT030600 - KT030609 11579 ARC-OVI OIE Laboratory Reference Strain AHSV4 [44], TS
African horse sickness virus 5 strain 5/Labstr/ZAF/1962/OVI-HS30/62 5/Lab/ZAF/62/OVI-HS30/62 SAMN03765194 KT030610 - KT030619 8637 ARC-OVI OIE Laboratory Reference Strain AHSV5 [44], TS
African horse sickness virus 6 strain 6/Labstr/ZAF/1963/OVI-HS39/63 6/Lab/ZAF/63/OVI-HS39/63 SAMN03765195 KT030620 - KT030629 12422 ARC-OVI OIE Laboratory Reference Strain AHSV6 [44], TS
African horse sickness virus 7 strain 7/Labstr/ZAF/1962/OVI-HS31/62 7/Lab/ZAF/62/OVI-HS31/62 SAMN03765197 KT030640 - KT030649 9632 ARC-OVI OIE Laboratory Reference Strain AHSV7 [44], TS
African horse sickness virus 8 strain 8/Labstr/KEN/1962/OVI-HS10/62 8/Lab/KEN/62/OVI-HS10/62 SAMN03765198 KT030650 - KT030659 9208 ARC-OVI OIE Laboratory Reference Strain AHSV8 [44], TS
African horse sickness virus 9 strain 9/Labstr/TCD/1961/OVI-HS90/61 9/Lab/TCD/61/OVI-HS90/61 SAMN03765199 KT030660 - KT030669 4957 ARC-OVI OIE Laboratory Reference Strain AHSV9 [44], TS
a Strain Name is formatted as follows: <virus name> strain <type>/<isolation host-suffix>/<country of sampling>/<year of sampling>/<variant designation>-<isolate designation> where <virus name> is the taxonomic name of the virus, <type> is the type of the virus strain, <isolation host-suffix> the first letter of genus name.full name of species 
from which the samples were collected and the suffix -tc indicates the strain was propagated on tissue culture, <country of sampling> is the ISO 3166-1 alpha-3 code for the country of sampling, <year of sampling> is the 4 digit year in which the sample was collected, <variant designation> is the name of the region in which the sample was 
collected and <isolate designation> is the laboratory code given to the specific sample. 
b Abbreviated Strain Name is formatted as follows: <type>/<isolation host-suffix>/<country of sampling>/<year of sampling>/<variant designation>-<isolate designation> where <type> is the type of the virus strain, <isolation host-suffix> four-letter format comprising first letter of genus name.first three letters of species from which the samples 
were collected and the suffix -tc indicated that the strain was propagated on tissue culture, <country of sampling> is the ISO 3166-1 alpha-3 code for the country of sampling, <year of sampling> is the 2 digit year in which the sample was collected and <variant designation> 3 letter code for the name of the region in which the sample was collected 
and <isolate designation> is the laboratory code given to the specific sample.
Technical Appendix 1. Metadata for each of the 39 AHSV type 1 field isolates from the 2004 Stellenbosch, 2011 Mamre, 2014 Porterville and 2014 Robertson outbreaks of AHS in the AHS Controlled Area of the Western Cape Province of South Africa. Each record includes the Strain Name of the isolate as submitted to 
GenBank, the Abbreviated Strain Name, a hyperlink to the Biosample details for the isolate, a hyperlink to the GenBank accession numbers for the isolate, the average coverage per nucleotide for the consensus sequences, the animal name or laboratory name from which the sample or material was sourced, reference 
numbers for publications that have previously described these cases or isolates, the genotype group of the field isolate, the outcome of the case, the type off samples submitted for examination, the date that the samples were collected and the vaccination status of the donor horse.
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Technical Appendix Table 1. Summary of results of best-fit substitution models obtained using PhyML-SMS (Smart Model 
Selection) with the Akaike information criterion for the concatenated alignments of the complete AHSV genomes and individual 
AHSV gene segments of the strains included in this study 
Gene Model Proportion invariable Rate category Gamma shape 
Genome GTR +G6 0 6 0.136 
VP1 GTR +G6 0 6 0.261 
VP2 GTR +G6 +I 0.186 6 1.196 
VP3 GTR +G6 0 6 0.157 
VP4 GTR +G6 +I 0.44 6 0.874 
VP5 GTR +G6 +I 0.356 6 0.599 
VP6 GTR +G6 0 6 0.459 
VP7 GTR +G6 +I 0.616 6 1.379 
NS1 GTR +G6 +I 0.606 6 1.184 
NS2 GTR 0 1  
NS3 GTR +G6 0 6 0.652 
 
Technical Appendix Table 2. RAMI indices describing the microdiverse genotype groups identified in AHSV-1 isolates from the 
2004, 2011, and 2014 outbreaks of AHS in the Western Cape Province of South Africa 
Cluster Abundance Xdistance Xdepth, nearest Xdepth, deepest Ydistance Ydepth, nearest Ydepth, deepest 
1a 4 0.00011 0.000055 0.000055 0.120843 0.000274 0.17623 
1b 11 0.000067 0.000034 0.000034 0.113798 0.004972 0.165405 
1c 1 0 0 0    
2 7 0.00033 0.000102 0.000187 0.120925 0.00036 0.176316 
3a 14 0.000121 0.000041 0.000062 0.114587 0.000173 0.166889 
3b 2 0.000459 0.000229 0.000229 0.114779 0.000375 0.167091 
Other 1 0 0 0    
Average 6.5 0.0002174 0.0000922 0.0001134 0.1169864 0.0012308 0.1703862 
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Technical Appendix Table 3. Summary statistics (p values) of tests for reassortment of gene segments of AHSV using 7 methods 
incorporated within RDP4 
Method 
Gene 
VP1 VP4 VP5 VP7 NS3 
RDP NS NS 3.60x10–298 1.22x10–31 6.17x10–238 
GENECONV NS 5.83x10–2 1.87x10–293 1.13x10–31 9.31x10–240 
Bootscan NS 7.66x10–4 2.95x10–298 1.22x10–31 5.55x10–238 
Maxchi NS NS 3.55x10–46 1.39x10–5 1.25x10–37 
Chimaera NS NS 8.97x10–48 5.93x10–5 9.88x10–38 
SiSscan NS NS 1.29x10–63 6.38x10–6 2.30x10–45 
3Seq 2. 27x10–12 NS 1.22x10–13 NS 2.20x10–182 
 
Technical Appendix Table 4. Summary of single nucleotide variants (SNVs) observed in NS1 of 1/Lab/ZAF/98/OBP-116 and 
3/Lab/ZAF/98/OBP-116 vaccine derived strains and strains isolated during 2014 AHS outbreaks in Porterville and Robertson 
Position 
Virus strains 
1/OBP-116 (+11) 3/OBP-116 1/Srn-WC00481 1/RB00008 1/RB00221 
839 (268)* U (A)† U (A) U (A) A (A) A (A) 
884 (283) U (Y) U (Y) C (Y) U (Y) U (Y) 
1126 (264) U (I) C (T) U (I) C (T) C (T) 
1191 (386) U (L) U (L) U (L) C (L) C (L) 
1382 (449) G (T) G (T) G (T) G (T) A (T) 
1392 (453) G (E) G (E) G (E) C (Q) C (Q) 
*Position given as nucleotide and (amino acid). 
†SNVs given as nucleotide and (amino acid). 
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Technical Appendix Figure 1. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP1 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS controlled area to the AHSV live, attenuated vaccine and reference viruses. Branches are 
scaled to represent numbers of inferred nucleotide differences per site with the scale bar at the bottom of 
the tree indicating genetic distance. Branches supported by full maximum-likelihood bootstrap values 
>70% are indicated. Genotype groups are indicated with brackets and group names to the right of the 
tree. 
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Technical Appendix Figure 2. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP2 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS controlled area to the AHSV live, attenuated vaccine and reference viruses. 
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Technical Appendix Figure 3. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP3 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS controlled area to the AHSV live, attenuated vaccine and reference viruses. 
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Technical Appendix Figure 4. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP4 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS controlled area to the AHSV live, attenuated vaccine and reference viruses. 
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Technical Appendix Figure 5. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP5 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS controlled area to the AHSV live, attenuated vaccine and reference viruses. 
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Technical Appendix Figure 6. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP6 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS Controlled Area to the AHSV live, attenuated vaccine and reference viruses. 
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Technical Appendix Figure 7. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated VP7 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS Controlled Area to the AHSV live, attenuated vaccine and reference viruses. 
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Technical Appendix Figure 8. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated NS1 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS Controlled Area to the AHSV live, attenuated vaccine and reference viruses. 
 
 
 Page 11 of 12 
 
 
Technical Appendix Figure 9. Maximum-likelihood phylogenetic tree indicating the genetic relationships 
of concatenated NS2 nucleotide sequences from affected horses in the 2004, 2011 and 2014 outbreaks 
in the AHS Controlled Area to the AHSV live, attenuated vaccine and reference viruses. 
 
 Page 12 of 12 
 
 
Technical Appendix Figure 10. Maximum-likelihood phylogenetic tree indicating the genetic 
relationships of concatenated NS3 nucleotide sequences from affected horses in the 2004, 2011 and 
2014 outbreaks in the AHS Controlled Area to the AHSV live, attenuated vaccine and reference viruses. 
